| 000 | 01836 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516205754.0 | ||
| 264 | 0 | _c20141022 | |
| 008 | 201410s 0 0 eng d | ||
| 022 | _a1536-0075 | ||
| 024 | 7 |
_a10.1080/15265161.2014.889240 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDeMarco, Joseph P | |
| 245 | 0 | 0 |
_aIs there an ethical obligation to disclose controversial risk? A question from the ACCORD Trial. _h[electronic resource] |
| 260 |
_bThe American journal of bioethics : AJOB _c2014 |
||
| 300 |
_a4-10 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xblood |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aClinical Trials Data Monitoring Committees |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xethics |
| 650 | 0 | 4 | _aCodes of Ethics |
| 650 | 0 | 4 | _aDecision Making |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEthics Committees, Research |
| 650 | 0 | 4 | _aEthics, Research |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInformed Consent _xethics |
| 650 | 0 | 4 |
_aMetformin _xadministration & dosage |
| 650 | 0 | 4 | _aMoral Obligations |
| 650 | 0 | 4 |
_aMortality _xtrends |
| 650 | 0 | 4 |
_aResearch Personnel _xethics |
| 650 | 0 | 4 | _aResearch Subjects |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aSulfonylurea Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aTherapeutic Equipoise |
| 650 | 0 | 4 |
_aTruth Disclosure _xethics |
| 650 | 0 | 4 | _aUncertainty |
| 700 | 1 | _aFord, Paul J | |
| 700 | 1 | _aPatton, Dana J | |
| 700 | 1 | _aStewart, Douglas O | |
| 773 | 0 |
_tThe American journal of bioethics : AJOB _gvol. 14 _gno. 4 _gp. 4-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/15265161.2014.889240 _zAvailable from publisher's website |
| 999 |
_c23735216 _d23735216 |
||